On July 23 and 24, 2026, the US Food and Drug Administration's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c and other peptides for possible inclusion on the section 503A bulk drug substances list, which governs what US compounding pharmacies may prepare
While results can vary and more human studies are needed to validate many of the claims surrounding BPC-157, the early feedback and preclinical research suggest promising directions-especially when it comes to natural recovery, resilience, and performance support
TB500, a synthetic version of thymosin beta-4, a naturally occurring protein, complements these effects by enhancing cell migration, reducing inflammation, and supporting the repair of muscles, tendons, and ligaments
Consider research goals and circumstances to determine the administration method that aligns best with the study and needs